Ramagopalan SV, Dobson R, Meier UC, Giovannoni G. Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol. 2010;9:727–39.

Article  PubMed  Google Scholar 

Alfredsson L, Olsson T. Lifestyle and Environmental Factors in Multiple Sclerosis. Cold Spring Harb Perspect Med [Internet]. 2019;9. Available from: https://doi.org/10.1101/cshperspect.a028944

International Multiple Sclerosis Genetics Consortium. A systems biology approach uncovers cell-specific gene regulatory effects of genetic associations in multiple sclerosis. Nat Commun. 2019;10:2236.

Article  Google Scholar 

Giovannoni G. The neurodegenerative prodrome in multiple sclerosis. Lancet Neurol. 2017;16:413–4.

Article  PubMed  Google Scholar 

Munger KL, Levin LI, O’Reilly EJ, Falk KI, Ascherio A. Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel. Mult Scler. 2011;17:1185–93.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pakpoor J, Giovannoni G, Ramagopalan SV. Epstein-Barr virus and multiple sclerosis: association or causation? Expert Rev Neurother. 2013;13:287–97.

Article  CAS  PubMed  Google Scholar 

Levin LI, Munger KL, O’Reilly EJ, Falk KI, Ascherio A. Primary infection with the Epstein-Barr virus and risk of multiple sclerosis. Ann Neurol. 2010;67:824–30.

Article  PubMed  PubMed Central  Google Scholar 

Pakpoor J, Disanto G, Gerber JE, Dobson R, Meier UC, Giovannoni G, et al. The risk of developing multiple sclerosis in individuals seronegative for Epstein-Barr virus: a meta-analysis. Mult Scler. 2013;19:162–6.

Article  PubMed  Google Scholar 

Bjornevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, Leng Y, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science [Internet]. 2022; Available from: https://doi.org/10.1126/science.abj8222

Lanz TV, Robinson WH, Ho PP, Steinman L. Roadmap for understanding mechanisms on how Epstein-Barr virus triggers multiple sclerosis and for translating these discoveries in clinical trials. Clin Transl Immunology. 2023;12:e1438.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Läderach F, Münz C. Altered Immune Response to the Epstein-Barr Virus as a Prerequisite for Multiple Sclerosis. Cells [Internet]. 2022;11. Available from: https://doi.org/10.3390/cells11172757

Sospedra M, Martin R. Molecular mimicry in multiple sclerosis. Autoimmunity. 2006;39:3–8.

Article  CAS  PubMed  Google Scholar 

Martin R, Sospedra M, Eiermann T, Olsson T. Multiple sclerosis: doubling down on MHC. Trends Genet. 2021;37:784–97.

Article  CAS  PubMed  Google Scholar 

Lanz TV, Brewer RC, Ho PP, Moon J-S, Jude KM, Fernandez D, et al. Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. Nature. 2022;603:321–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vietzen H, Berger SM, Kühner LM, Furlano PL, Bsteh G, Berger T, et al. Ineffective control of Epstein-Barr-virus-induced autoimmunity increases the risk for multiple sclerosis. Cell. 2023;186:5705-18.e13.

Article  CAS  PubMed  Google Scholar 

Hill AB. THE ENVIRONMENT AND DISEASE: ASSOCIATION OR CAUSATION? Proc R Soc Med. 1965;58:295–300.

CAS  PubMed  PubMed Central  Google Scholar 

Giovannoni G. Epstein-Barr Virus and MS. Int MS J. 2011;17:44–9.

CAS  PubMed  Google Scholar 

Giovannoni G, Cutter GR, Lunemann J, Martin R, Münz C, Sriram S, et al. Infectious causes of multiple sclerosis. Lancet Neurol. 2006;5:887–94.

Article  PubMed  Google Scholar 

Taylor D, Almond J, Ascherio A, Cohen J, Cuzick J, Giovannoni G, et al. Report of the Wolfson Institute Workshop on Epstein Barr Virus Infection and Multiple Sclerosis Prevention. 2017.

Maple PA, Ascherio A, Cohen JI, Cutter G, Giovannoni G, Shannon-Lowe C, et al. The Potential for EBV Vaccines to Prevent Multiple Sclerosis. Front Neurol. 2022;13:887794.

Article  PubMed  PubMed Central  Google Scholar 

Nelson P, Rylance P, Roden D, Trela M, Tugnet N. Viruses as potential pathogenic agents in systemic lupus erythematosus. Lupus. 2014;23:596–605.

Article  CAS  PubMed  Google Scholar 

Bakkalci D, Jia Y, Winter JR, Lewis JE, Taylor GS, Stagg HR. Risk factors for Epstein Barr virus-associated cancers: a systematic review, critical appraisal, and mapping of the epidemiological evidence. J Glob Health. 2020;10:010405.

Article  PubMed  PubMed Central  Google Scholar 

Rühl J, Leung CS, Münz C. Vaccination against the Epstein-Barr virus. Cell Mol Life Sci. 2020;77:4315–24.

Article  PubMed  PubMed Central  Google Scholar 

van Zyl DG, Mautner J, Delecluse H-J. Progress in EBV Vaccines. Front. Oncol. 2019;9:104.

Google Scholar 

Aloisi F, Giovannoni G, Salvetti M. Epstein-Barr virus as a cause of multiple sclerosis: opportunities for prevention and therapy. Lancet Neurol. 2023;22:338–49.

Article  PubMed  Google Scholar 

Giovannoni G, Hawkes CH, Lechner-Scott J, Levy M, Yeh EA, Gold J. Is EBV the cause of multiple sclerosis? Mult Scler Relat Disord. 2022;58:103636.

Article  PubMed  Google Scholar 

Handel AE, Williamson AJ, Disanto G, Handunnetthi L, Giovannoni G, Ramagopalan SV. An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis. PLoS One [Internet]. 2010;5. Available from: https://doi.org/10.1371/journal.pone.0012496

Thacker EL, Mirzaei F, Ascherio A. Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann Neurol. 2006;59:499–503.

Article  PubMed  Google Scholar 

Hedström AK, Huang J, Michel A, Butt J, Brenner N, Hillert J, et al. High Levels of Epstein-Barr Virus Nuclear Antigen-1-Specific Antibodies and Infectious Mononucleosis Act Both Independently and Synergistically to Increase Multiple Sclerosis Risk. Front Neurol. 2019;10:1368.

Article  PubMed  Google Scholar 

Pender MP, Csurhes PA, Smith C, Douglas NL, Neller MA, Matthews KK, et al. Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis. JCI Insight [Internet]. 2018;3. Available from: https://doi.org/10.1172/jci.insight.124714

Baker D, Marta M, Pryce G, Giovannoni G, Schmierer K. Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis. EBioMedicine. 2017;16:41–50.

Article  PubMed  PubMed Central  Google Scholar 

Baker D, Pryce G, James LK, Schmierer K, Giovannoni G. Failed B cell survival factor trials support the importance of memory B cells in multiple sclerosis. Eur J Neurol. 2020;27:221–8.

Article  CAS  PubMed  Google Scholar 

Giovannoni G. Targeting Epstein-Barr virus in multiple sclerosis: when and how? Curr Opin Neurol. 2024;37:228–36.

Article  CAS  PubMed  Google Scholar 

Pender MP, Burrows SR. Epstein-Barr virus and multiple sclerosis: potential opportunities for immunotherapy. Clin Transl Immunology. 2014;3:e27.

Article  PubMed  PubMed Central  Google Scholar 

Pender MP, Csurhes PA, Pfluger CM, Burrows SR. Deficiency of CD8+ effector memory T cells is an early and persistent feature of multiple sclerosis. Mult Scler. 2014;20:1825–32.

Article  PubMed  PubMed Central  Google Scholar 

Bar-Or A, Pender MP, Khanna R, Steinman L, Hartung H-P, Maniar T, et al. Epstein-Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies. Trends Mol Med. 2020;26:296–310.

Article  CAS  PubMed  Google Scholar 

Atara. Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis [Internet]. Atara Biotherapeutics. 2023 [cited 2023 Nov 29]. Available from: https://investors.atarabio.com/news-events/press-releases/detail/330/atara-biotherapeutics-announces-primary-analysis-data-from

Noteboom S, Arnold D, Bar-Or A, Pender M, Hodgkinson S, Broadley S, et al. Long-term disability improvement during EBV-targeted T-cell immunotherapy ATA188 is related to brain volume change and normalised magnetisation transfer ratio in T2 lesions. Mult Scler J. 2022;28:1006–7.

Google Scholar 

Bar-Or A, Pender MP, Hodgkinson SJ, Broadley S, Lindsey JW, Ioannides ZA, et al. Updated open-label extension clinical data and new magnetization transfer ratio imaging data from a phase I study of ATA188, an off-the-shelf, allogeneic Epstein-Barr virus-targeted T-cell immunotherapy for progressive multiple sclerosis. MULTIPLE SCLEROSIS JOURNAL. SAGE PUBLICATIONS LTD 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND; 2022. p. 72–72.

Smith C, Khanna R. Adoptive T-cell therapy targeting